Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E-Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth

Circulation

Volumn 109, Issue 11, 2004, Pages 1408-1414

  Luttun, Aernout ^a   Lutgens, Esther ^b   Manderveld, Ann ^a   Maris, Katleen ^a   Collen, Désiré ^a   Carmeliet, Peter ^a   Moons, Lieve ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Aneurysm; Atherosclerosis; Collagen; Hypercholesterolemia; Metalloproteinases

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; COLLAGEN; ELASTIN; GELATINASE B; MACROPHAGE ELASTASE; PLASMINOGEN ACTIVATOR; UROKINASE;

ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTERY ECTASIA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DAMAGE; CHOLESTEROL INTAKE; COLLAGEN METABOLISM; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; COLLAGEN; DIET, ATHEROGENIC; DILATATION, PATHOLOGIC; ELASTIN; EXTRACELLULAR MATRIX; FEMALE; HYPERCHOLESTEROLEMIA; MACROPHAGES; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; TUNICA MEDIA;

EID: 1642362387     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000121728.14930.DE     Document Type: Article

References (30)

1. Henney AM, Ye S, Zhang B, et al. Genetic diversity in the matrix metalloproteinase family: effects on function and disease progression. Ann N Y Acad Sci. 2000;902:27-37; discussion 37-38.
2. Lindholt JS, Vammen S, Fasting H, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms: a preliminary study. Eur J Vasc Endovasc Surg. 2000; 20:281-285.
3. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
4. Carrell TW, Burnand KG, Wells GM, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation. 2002; 105:477-482.
5. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation. 1999;100: 533-540.
6. Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 1998;102:1413-1420.
7. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res. 2002;90: 897-903.
8. Lemaitre V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation. 2003; 107:333-338.
9. Moore G, Liao S, Curci JA, et al. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg. 1999;29:522-532.
10. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms: rationale for a prospective randomized clinical trial. Ann N Y Acad Sci. 1999;878:159-178.
11. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444.
12. Silence J, Lupu F, Collen D, et al. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440-1445.
13. Lemaitre V, O'Byrne TK, Borczuk AC, et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:1227-1234.
14. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
15. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110: 625-632.
16. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499-505.
17. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5: 1135-1142.
18. Nunnari JJ, Zand T, Joris I, et al. Quantitation of Oil Red O staining of the aorta in hypercholesterolemic rats. Exp Mol Pathol. 1989;51:1-8.
19. Lesauskaite V, Tanganelli P, Sassi C, et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol. 2001;32:1003-1011.
20. Newby AC, Zaltsman AB. Fibrous cap formation or destruction: the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 1999;41:345-360.
21. Fitzgerald M, Hayward IP, Thomas AC, et al. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis. 1999;145:97-106.
22. Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1029-1034.
23. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859.
24. Shipley JM, Wesselschmidt RL, Kobayashi DK, et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A. 1996;93:3942-3946.
25. Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277:2002-2004.
26. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
27. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol. 1998;9:413-423.
28. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
29. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623-628.
30. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.